Teva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45
Teva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45
Teva預計2024年調整後每股收益爲2.40-2.50美元，而先前指引爲2.30-2.50美元，共識爲2.45美元。
Outlook for 2024 Non-GAAP Results
2024年調整後非公認會計原則結果展望
| $ billions, except EPS or as noted | November 2024 Outlook | July 2024 Outlook | February 2024 Outlook |
| Revenues* | $16.1 - $16.5 | $16.0 - $16.4 | $15.7 - $16.3 |
| AUSTEDO ($m)* | ~1,600 | ~1,600 | ~1,500 |
| AJOVY ($m)* | ~500 | ~500 | ~500 |
| UZEDY ($m)* | ~100 | ~80 | ~80 |
| COPAXONE ($m)* | ~500 | ~450 | ~400 |
| Operating Income | 4.2 - 4.5 | 4.1 - 4.5 | 4.0 - 4.5 |
| Adjusted EBITDA | 4.7 - 5.0 | 4.6 - 5.0 | 4.5 - 5.0 |
| Finance Expenses ($m) | ~1,000 | ~1,000 | ~1,000 |
| Tax Rate | 14% - 17% | 14% - 17% | 14% - 17% |
| Diluted EPS ($) | 2.40 - 2.50 | 2.30 - 2.50 | 2.20 - 2.50 |
| Free Cash Flow** | 1.7 - 2.0 | 1.7 - 2.0 | 1.7 - 2.0 |
| CAPEX* | ~0.5 | ~0.5 | ~0.5 |
| Foreign Exchange | Volatile swings in FX can negatively impact revenue and income | ||
| 十億美元，除每股收益或特別說明外 | 2024年11月展望 | 2024年7月展望 | 2024年2月展望 |
| 營業收入* | $16.1 - $16.5 | $16.0 - $16.4 | $15.7 - $16.3 |
| AUSTEDO（$百萬）* | ~1,600 | ~1,600 | ~1,500 |
| AJOVY（$百萬）* | ~500 | ~500 | ~500 |
| UZEDY（百萬美元）* | ~100 | ~80 | ~80 |
| COPAXONE（百萬美元）* | ~500 | ~450 | ~400 |
| 營業收入 | 4.2 - 4.5 | 4.1 - 4.5 | 4.0 - 4.5 |
| 調整後的EBITDA | 4.7 - 5.0 | 4.6 - 5.0 | 4.5 - 5.0 |
| 財務費用（百萬美元） | ~1,000 | ~1,000 | ~1,000 |
| 稅率 | 14% - 17% | 14% - 17% | 14% - 17% |
| 攤薄後每股收益($) | 2.40 - 2.50 | 2.30 - 2.50 | 2.20 - 2.50 |
| 自由現金流** | 1.7 - 2.0 | 1.7 - 2.0 | 1.7 - 2.0 |
| CAPEX* | ~0.5 | ~0.5 | ~0.5 |
| 匯率期貨 | 外匯波動可能會對營業收入和收益產生負面影響 | ||
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間